Ibogaine Clinical Guidelines

Ibogaine Therapy Information For Clinicians " 2014

Ibogaine Therapy Information For CliniciansIbogaine Te Wai PounamuIbogaine: Information and Guide Lines for Integrated TherapyDeveloped by I.ACT 2014Ibogaine Therapy Information For CliniciansIbogaine Te Wai PounamuIbogaine: Information and Guide Lines for Integrated TherapyDeveloped by I.ACT 2014


Ibogaine Therapy Information For Clinicians
Ibogaine Te Wai Pounamu
Ibogaine: Information and Guide Lines for Integrated Therapy

Developed by I.ACT
2014



Ibogaine Therapy Information For Clinicians
Ibogaine Te Wai Pounamu
Ibogaine: Information and Guide Lines for Integrated Therapy

Developed by I.ACT
2014


Brief Explanation of Ibogaine
Including excerpts from Wikipedia, the free encyclopaedia.
Ibogaine is one of at least 12 naturally occurring psychoactive or psychotropic substance found in West African plants such as Tabernanthe iboga, Voacanga africana and Tabernaemontana undulata. Ibogaine is a dream inducing or 'Oneiric' substance often referred to as a hallucinogen with both psychedelic and dissociative properties. Ibogaine is scheduled in some countries due to these properties, however it has been shown to have a low to zero abuse potential and no addictive properties have been noted.
In many countries it is being used to treat substance dependence including methadone, heroin, alcohol, cocaine, and methamphetamine. Derivatives of ibogaine that lack the substance's hallucinogenic properties (notably nor-ibogaine) are currently under development.
Ibogaine-containing preparations are used in medicinal and ritual purposes within West African spiritual traditions of the Bwiti. It was first commonly advertised as having anti-addictive properties in 1962 by Howard Lotsof. However Ibogaine has western use that predates that by at least a century. For example, in the 1830's the French marketed ibogaine hcl as Lambarene (4-8mg caps), a medicinal pill used as a stimulant, aphrodisiac and post viral recovery substance.
The prohibition of ibogaine in several countries has slowed scientific research into its anti-addictive properties. In February 2010 Medsafe New Zealand approved the use of ibogaine hcl under section 29 of the 1981 Medicines Act.
Ibogaine







History and Procedure in the Treatment of Opioid Cessation with Ibogaine

In February 2010 Medsafe reclassified Ibogaine hydrochloride as a non-approved prescription medication to be used in the treatment of chemical dependence on substances, primarily opioids. This document is specifically designed for clinicians working in the area of substance use. Ibogaine Therapy is beneficial to those wishing to cease or interrupt their dependence on opioids.

Ibogaine Aotearoa Charitable Trust or I.ACT was set up in September of 2009 to support bringing the option of ibogaine to consumers wishing to cease their dependence on substances, notably opioids. I.ACT developed a good practise model specifically around the status of ibogaine in Aotearoa/NZ and the provision for integration into the existing therapeutic options. This was designed to implement an environment for ibogaine therapy to move forward locally and globally in a sustainable and respectful way.



Inclusion and Exclusion Criteria

Inclusion Criteria
Tangata Whaiora, the Person Seeking Help
Has a desire to cease dependence on opioids, is motivated to change and who understands that ibogaine therapy alone is not a 'cure'
Signs an informed consent and has a clear understanding of the risks and benefits of ibogaine therapy
Is willing to be a part of a process that includes adhering to provider and clinicians requests to attend appointments and do the appropriate medical testing and comprehensive assessment with utmost honesty
Takes the responsibility of engaging with any services that they have been referred to and continue with ongoing self-care.
Understands that the provider obligations will end at 6 weeks post ibogaine therapy unless prior formal arrangement has been made for extended support.
Is self-funded or willing to seek out funding privately for their tx



Exclusion Criteria
Cardiac issues; investigate, prolonged qt interval, peri-carditis, history of cardiac issues and high cholesterol levels
Kidney, gastro-intestinal disease (further investigation)
Compromised liver function. Active chronic hep c where normal levels are above 4 x the normal range.
History of active neurological or psychiatric disorders, such as cerebellar dysfunction, epilepsy, psychosis, bipolar illness, schizophrenia, organic brain disease or dementia that require ongoing treatment.
Currently pregnant or breastfeeding unless a weaning plan is incorporated into the therapeutic plan prior to tx
Inadequate home environment to return to i.e. living alone with no support, living situation indicative of continued drug use (partner/whanau/flatmates still in active use) In this case extra support plans and risk management plans must be put in place prior to tx. Residential care post ibogaine tx should be discussed in this case
Currently taking prescribed and non-prescribed medication (supplements and/or street drugs) contraindicated with ibogaine. Discuss on a case by case basis


Medication considerations
Levels of methadone over 40 mgs must reduce to